Patient perspective on living with mild hemophilia in Germany: results from a nationwide survey

Autor: Rosa Sonja Alesci, Georg Goldmann, Susan Halimeh, Katharina Holstein, Christoph Königs, Wolfgang Miesbach, Christian Pfrepper, Martin Olivieri

Publikováno v: Frontiers in Medicine, Vol 11 (2024)

IntroductionThe disease burden and bleeding risk of patients with mild hemophilia may be underestimated. Their health-related quality of life (QoL) may be negatively impacted by insufficient treatment and bleed-related joint damage connected to a pot

Externí odkaz: https://doaj.org/article/19f8d462bcaa46e585eedb6913bcf9bd

Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A

Autor: Tomasz Urasiński, Klaudia Paczóska, Wanda Badowska, Halina Bobrowska, Łucja Dakowicz, Grzegorz Dobaczewski, Elżbieta Latos-Grażyńska, Grażyna Karolczyk, Anna Klukowska, Andrzej Kołtan, Magdalena Wojdalska, Paweł Łaguna, Maciej Niedźwiedzki, Danuta Pietrys, Julia Radoń-Proskura, Monika Radwańska, Iwona Rurańska, Tomasz Szczepański, Dariusz Wasiński, Irena Woźnica-Karczmarz, Karolina Zielezińska, Aleksandra Królak, Tomasz Ociepa

Publikováno v: Frontiers in Pediatrics, Vol 11 (2023)

IntroductionIn 2020, the new nationwide protocol of prophylaxis in Polish plasma-derived FVIII (pdFVIII) previously treated patients (PTPs) with severe hemophilia A (sHA) was introduced, resulting in the necessity of switching from pdFVIII to recombi

Externí odkaz: https://doaj.org/article/b937e71489a94a3f929880c7587f2bdc

Clinical and laboratory evaluation of adult Hemophilia A and Hemophilia B patients single center experience

Autor: Tekin, Salih, Karakuş, Abdullah, Demircan, Vehbi, Ayyıldız, Orhan

Publikováno v: Dicle Tıp Dergisi. :96-101

Amaç: Hemofili, koagülasyon faktörlerinden faktör VIII (hemofili A) veya faktör IXʼun (hemofili B) eksikliğinden kaynaklanan X'e bağlı resesif kalıtım gösteren konjenital kanama bozukluğudur. Bu çalışmamızdaki amacımız hemofili has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b80b974c6356af61deec4b63636c3884
https://doi.org/10.5798/dicletip.1267180

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)

Autor: Manuel Carcao, Kingsley Hampton, Lars Korsholm, Robert Klamroth, Sonata Saulyte Trakymienė

Publikováno v: Patient preference and adherence
Patient preference and adherence, Auckland : Dove Medical Press Ltd, 2021, vol. 15, p. 2443-2454
Patient Preference and Adherence, Vol Volume 15, Pp 2443-2454 (2021)

Purpose To illustrate the benefits of the extended half-life (EHL) recombinant factor VIII product N8-GP (Esperoct®, turoctocog alfa pegol) by describing individual cases of patients with severe hemophilia A treated with N8-GP in the pathfinder clin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3110aed353e927dca096ac93b701e424
http://europepmc.org/articles/PMC8575374